

Note: This document has been translated from the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail.

March 26, 2026

Company name: ELAN Corporation
Name of representative: Tomohiro Minezaki, CEO
(Securities code: 6099; TSE Prime Market)
Inquiries: Akira Ishizuka, Director, Executive Officer, CSO, General Manager of Corporate Strategy Department
(Telephone: +81-263-41-0760)

Matters Concerning Controlling Shareholder, Etc.

We hereby notify you that the following information pertains to the controlling shareholders and related parties of M3, Inc., our parent company.

- Trade name, etc., of the parent company, controlling shareholder (excluding the parent company), other affiliated company, or parent company of another affiliated company

(As of December 31, 2025)

Name	Attribute	Ratio of voting rights held (%)			Financial instruments exchange, etc. on which the issued shares, etc. are listed
		Voting rights directly held	Voting rights subjects to aggregation	Total	
M3, Inc.	Parent Company	55.02	-	55.02	Tokyo Stock Exchange, Inc. Prime Market

- The Company's Position within the Parent Company's Corporate Group and Other Relationships between the Listed Company and the Parent Company

M3, Inc. is our parent company, holding 55.02% of our voting rights. The parent company group operates globally, primarily through various services including the medical professional platform “m3.com” used by over 340,000 physician members in Japan, platforms such as “MDLinx” in the U.S. and “Doctors.net.uk” in the U.K., and physician recruitment services. Our group is classified within the parent company's Patient Solution segment.

The status of concurrent positions held by officers as of the end of our most recent fiscal year (December 31, 2025) and after the Company's Annual General Meeting of Shareholders held on March 25, 2026, is as follows.

(As of March 25, 2026)

Position at ELAN Corporation	Name	Position at the parent company	Reason for appointment
Director	Yukiko Matsumoto	Corporate Officer, M3, Inc.	We have determined that her experience and expertise in marketing, product design, and project management within the healthcare business will contribute to the sustained enhancement of our group's corporate value.
Director (Audit and Supervisory Committee Member)	Hirofumi Oba	Corporate Officer, M3, Inc.	We have determined that his expertise in various corporate functions, including business management, accounting, and legal affairs/compliance, will contribute to enhancing the management capabilities of our group.

As of March 25, 2026, two directors of our company concurrently serve as officers or employees of M3, Inc., as stated above. This number represents a small proportion of our ten directors. Furthermore, we recognize that our company's management and business activities are conducted based on independent decision-making and in accordance with our management policies, ensuring a certain degree of independence.

3. Matters concerning transactions with controlling shareholder, etc.

During our most recent fiscal year (ended December 2025), there were no material transactions with controlling shareholders or related parties that required disclosure.

4. Implementation Status of Measures to Protect Minority Shareholders in Transactions with Controlling Shareholders

Regarding significant transactions or actions where conflicts of interest may arise between the parent company and our minority shareholders, the Board of Directors consults with a special committee composed of independent directors in accordance with internal regulations. The Board of Directors then makes decisions while respecting the special committee's recommendations.